Clinical Trials Logo

Filter by:
NCT ID: NCT05429047 Recruiting - COVID-19 Clinical Trials

Priming of the NEonatal Immune System by Transfer of Maternal Immunity

NEST
Start date: June 7, 2022
Phase:
Study type: Observational

Newborn babies and infants are susceptible to infections as their immune system is still immature. Maternal immune factors for example antibodies and immune cells mitigate this vulnerability. They are transferred from mother to child via the placenta during pregnancy or by breast milk after birth and provide protection against infectious diseases. In the case of SARS-CoV-2 it has already been shown that specific antibodies are transferred from mother to children after infection or vaccination during pregnancy. However, to this date it is not known how long such an antibody-mediated protection lasts in children and if this "passive" immunity actually protects infants from SARS-CoV-2 infection in the first months of life. In general, there is still little knowledge about the influence of maternal infections during pregnancy, transfer of maternal immune factors to the child and development of the child's immune system and health in the first months of life. Here, the investigators aim to study transferred immunity (i.e. specific antibodies) against SARS-CoV-2 in children of mothers who received a SARS-CoV-2 vaccination during pregnancy or had a SARS-CoV-2 infection during pregnancy with mothers not exposed or exposed before pregnancy. In addition, the investigators will comprehensively characterize the development of the cellular immune system in the first year of life (umbilical cord blood, age 6 and 12 months) to explore how maternal exposure to infectious diseases or vaccines influences the development of the immune system of the newborn infant.

NCT ID: NCT05428397 Not yet recruiting - Clinical trials for Need for a Contrast Enhanced X-ray Based Examination

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Start date: June 30, 2022
Phase:
Study type: Observational

This is an observational study in which patient data from the past of people who received Ultravist prior to an X-ray based scan are studied. In observational studies, only observations are made without specified advice or interventions. X-ray based imaging like computed tomography or angiography is used to make pictures of the structures inside the body. These pictures are needed in various medical situations. In some X-ray tests, the patient is given a compound called "contrast agent" that is injected into the vein. It helps to create clearer pictures as it makes internal body structures easier to see. With such contrast-enhanced imaging techniques, doctors can better see certain problems. Ultravist is an iodine-based contrast agent. It is also called iopromide, and it is available for doctors to give patients before they have X-ray based scans. Clinical studies on the overall safety of Ultravist have shown that hypersensitivity reactions (HSRs) may rarely occur. HSRs are undesirable reactions of the body's defense system (immune system) to the study drug. However, more information on HSRs is needed. The main aim of this study is to find out whether certain groups of people are more likely to have HSRs after Ultravist injection than others (e.g., depending on gender, race, or country/region). To do this, researchers will collect data from people with HSRs (all ages) after contrast-enhanced X-ray scans with Ultravist. These data come from four observational studies that have already been completed. Participants who had HSRs will be compared with participants in these studies who had no medical problems after receiving Ultravist to learn more about the characteristics of people at higher risk. Data will be from the year 1999 up to 2011. No visits or tests are required as part of this study.

NCT ID: NCT05426239 Completed - Advanced Melanoma Clinical Trials

Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German Database

Start date: January 9, 2019
Phase:
Study type: Observational

This study is a non-interventional retrospective observational study performed on secondary data from a German multi-site cohort registry, the German national registry of skin cancer (ADOReg).

NCT ID: NCT05425771 Not yet recruiting - Clinical trials for Reflux, Gastroesophageal

ARMA (Antireflux Mucosa Ablation) in Patients With Chronic Refractory Reflux Disease

ARMA
Start date: June 15, 2022
Phase: N/A
Study type: Interventional

Pilot study of the possible clinical response to anti reflux mucosal ablation in patients with chronic refractory reflux disease

NCT ID: NCT05425251 Recruiting - Clinical trials for Mild Traumatic Brain Injury

BRAINI-2 Elderly Mild TBI European Study

BRAINI2ELDER
Start date: March 1, 2022
Phase:
Study type: Observational

Mild traumatic brain injury (mTBI) is one of the most frequent emergencies in the elderly population. Despite most mTBI are managed with cranial computed tomography (CT), only 10% of CTs show lesions, determining CT overuse. The use of serum glial fibrillary acidic protein (GFAP) and Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) have shown potential for ruling out the need for cranial CT. However evidence on biomarker use in mild TBI were not based on studies that included aged participants and patients with comorbidities for which biomarker levels could vary. This is why there is a need for a prospective study that assesses the predictive performance of these two biomarkers in the elderly population, both in elderly patients suffering mild TBI and in a reference population, including patients and participants with and without comorbidities.

NCT ID: NCT05424965 Active, not recruiting - Clinical trials for Gestational Diabetes Mellitus in Pregnancy

Cologne Placenta Cohort (CPC)

Start date: March 23, 2018
Phase:
Study type: Observational

Aim of the study was to determine if signaling pathways in placentas of mothers affected by overweight/obesity or by gestational diabetes are altered compared to placentas of a control group (normal weight, no gestational diabetes). Moreover, maternal blood and umbilical cord blood were analysed.

NCT ID: NCT05424250 Recruiting - Arachnophobia Clinical Trials

Optimizing Exposure Using Occasional Aversive Imagery in Spider Fearful Individuals

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

The effectiveness of an optimized extinction training is investigated in spider-fearful individuals. Participants will undergo a one-session standardized extinction training, either with or without occasional metal imagination of most feared apprehension towards spiders. The effectiveness of the training is measured by symptom improvement according to subjective ratings and behavioural avoidance tests one week later.

NCT ID: NCT05422859 Not yet recruiting - Heart Failure Clinical Trials

Mobile and Digital Application in Heart Failure Networks Berlin/Brandenburg

MobiDig
Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The MobiDig trial is designed to evaluate an implementation of a mobile phone application with secondary preventive/rehabilitative modules for patients with heart failure in certified Heart Failure Unit centers in Berlin and Brandenburg. The aim is to evaluate the effect on quality of life, symptoms and the course of the disease. In addition, the acceptance, adherence and user behavior as well as the implementation potential for a permanent introduction of the application in national heart failure networks will be analyzed.

NCT ID: NCT05422170 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

Heparin During TAVI

HepaTAVI
Start date: July 1, 2022
Phase:
Study type: Observational

Unfractioned heparin is usually given in a defined dosage during transfemoral TAVI. Activated Clotting Time (ACT) is usually used to measure the heparin effect. ACT-analysis is easy to perform at the bedside, but susceptible to interference effects. At the end of the procedure, protamine is given to reverse eventual residual heparin effect.An overdose of protamine can impair the coagulation itself. We want wo analyse the effect of a partial heparin reversal by ROTEM Analysis

NCT ID: NCT05421286 Not yet recruiting - Inflammation Clinical Trials

The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events

MISTRAL
Start date: July 1, 2022
Phase:
Study type: Observational [Patient Registry]

MISTRAL (Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination) is a 5-year EU Horizon 2020 project, running from 1/1/2020 - 31/12/2024. The project is led by Fundacio Privada Institut de Recerca de la Sida-Caixa CAIXA in Barcelona and aims to explore the gut microbiota in relation to HIV-1, seeking microbiome biomarkers to support development of interventions that mitigate infection and enhance response to vaccines and therapies. If successful, MISTRAL will benefit millions of human beings living with, or at risk of acquiring HIV-1 infection, and will produce novel concepts and technical innovations applicable to other human diseases. By doing that, MISTRAL will help to unlock the full clinical potential of the human microbiome to stratify patient outcomes and will irreversibly bring microbiome science closer to clinical practice